Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,176,930.00 in Stock

Posted by Brenda Bartman on Oct 13th, 2026

United Therapeutics Corporation (NASDAQ:UTHR – Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $544.94, for a total value of $5,176,930.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $176,801,968.42. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

United Therapeutics Price Performance

Shares of NASDAQ:UTHR traded down $6.70 during midday trading on Tuesday, hitting $543.40. The company had a trading volume of 504,426 shares, compared to its average volume of 554,931. United Therapeutics Corporation has a twelve month low of $409.07 and a twelve month high of $609.35. The stock has a market cap of $23.31 billion, a price-to-earnings ratio of 19.44, a price-to-earnings-growth ratio of 2.73 and a beta of 0.49. The business’s 50-day simple moving average is $512.67 and its 200-day simple moving average is $540.26.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. The firm had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $6.41 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 26.40 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in UTHR. Toth Financial Advisory Corp grew its holdings in shares of United Therapeutics by 2,400.0% during the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 48 shares during the period. Fiduciary Financial Advisors acquired a new stake in shares of United Therapeutics during the 2nd quarter worth about $30,000. Caitlin John LLC purchased a new stake in United Therapeutics in the 2nd quarter valued at about $37,000. International Assets Investment Management LLC raised its holdings in United Therapeutics by 426.7% in the 1st quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the period. Finally, Keating Financial Advisory Services Inc. acquired a new position in United Therapeutics in the second quarter valued at about $81,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on UTHR shares. Royal Bank Of Canada lifted their price target on United Therapeutics from $677.00 to $708.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Cantor Fitzgerald reissued an “overweight” rating on shares of United Therapeutics in a research report on Thursday, October 1st. JPMorgan Chase & Co. upped their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Bank of America cut their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, Weiss Ratings cut shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, August 27th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $627.31.

View Our Latest Research Report on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for pulmonary arterial hypertension (PAH) and other serious cardiopulmonary conditions. The company’s products include Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable form of treprostinil; Orenitram, an oral treprostinil product; and Adcirca, a tadalafil-based PAH treatment.

United Therapeutics markets its therapies primarily in the United States and internationally through commercial and regulatory activities in additional markets.